Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Catalyst Pharmaceuticals’ dense biotech filings can feel like wading through clinical-trial data, patent tables, and risk factors that stretch for hundreds of pages. Investors searching for “Catalyst Pharmaceuticals SEC filings explained simply” or wondering how Firdapse® revenue moves the needle quickly discover the documents are anything but short. That’s where Stock Titan steps in.
Our AI-powered engine ingests every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR, then serves plain-English answers to questions you actually ask: “Catalyst Pharmaceuticals quarterly earnings report 10-Q filing,” “Catalyst Pharmaceuticals proxy statement executive compensation,” or “Catalyst Pharmaceuticals insider trading Form 4 transactions.” Interactive dashboards display “Catalyst Pharmaceuticals Form 4 insider transactions real-time,” while a single view of “Catalyst Pharmaceuticals executive stock transactions Form 4” reveals buying or selling trends before markets react. The platform’s narrative threads drug-sales shifts, R&D spend, and milestone payments into context you can act on.
Because Catalyst’s growth relies heavily on Firdapse® exclusivity and a focused rare-disease pipeline, even a single disclosure can reshape forecasts. Our summaries flag clinical-trial updates, FDA designations, and royalty agreements—“Catalyst Pharmaceuticals 8-K material events explained” without legal jargon. Dive deeper with “Catalyst Pharmaceuticals annual report 10-K simplified,” or launch an “understanding Catalyst Pharmaceuticals SEC documents with AI” walkthrough that pinpoints where orphan-drug incentives surface in the footnotes. Finally, AI-driven charts turn raw numbers into a “Catalyst Pharmaceuticals earnings report filing analysis,” clarifying revenue concentration, cash runway, and dilution risk—no white coat required.
Catalyst Pharmaceuticals (CPRX) President and CEO Richard J. Daly, who also serves as a director, reported new equity awards and related share activity. On November 21, 2025, he acquired 20,006 shares of common stock through the vesting of restricted stock units and had 7,872 shares withheld to cover taxes, leaving him with 238,928 shares of common stock held directly.
On November 20, 2025, he received options to purchase 381,948 shares of common stock at an exercise price of
Catalyst Pharmaceuticals (CPRX) director reports equity awards and vesting activity. A board member filed a Form 4 disclosing equity-based compensation and related share delivery in November 2025.
The reporting person was granted options to purchase 18,115 shares of common stock at an exercise price of $22.77 on November 20, 2025. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028. The filing also shows an award of 5,468 restricted stock units (RSUs) on November 20, 2025, each convertible into one share upon vesting.
On November 21, 2025, 947 RSUs were converted, and the corresponding 947 common shares were delivered to the director. Following these transactions, the director reports beneficial ownership of 496,026 shares of Catalyst Pharmaceuticals common stock directly, along with derivative holdings consisting of options and RSUs that will deliver additional shares as they vest over time.
Catalyst Pharmaceuticals (CPRX)November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. These options vest in three equal annual installments on November 20 of 2026, 2027, and 2028.
The officer was also granted 29,776 restricted stock units (RSUs), which convert into common shares upon vesting, with the same three-year vesting schedule. On November 21, 2025, 5,161 shares underlying RSUs were delivered, while 2,030 shares were withheld to cover taxes. After these transactions, the officer directly held 234,170 shares of common stock and 969,876 derivative securities, mainly options and RSUs.
Catalyst Pharmaceuticals, Inc. (CPRX) reported insider equity activity for its Chief Commercial Officer on a Form 4. On 11/21/2025, the officer exercised 5,603 shares of common stock and had 1,641 shares withheld to cover taxes, leaving 3,962 common shares beneficially owned directly. The filing also shows a grant on 11/20/2025 of options to purchase 106,873 shares of common stock at an exercise price of $22.77, vesting in three equal annual installments on November 20, 2026, 2027 and 2028. In addition, the officer received 32,257 restricted stock units tied to common stock, and RSUs covering 5,603 shares were settled into stock on 11/21/2025. Following these transactions, the officer holds 1,064,535 derivative securities, including options and RSUs, all reported as directly owned.
Catalyst Pharmaceuticals, Inc. (CPRX) director Daniel J. Curran reported new equity awards dated 11/20/2025. He received options to purchase 18,115 shares of common stock at an exercise price of $22.77 per share, which vest in three equal annual installments on November 20, 2026, 2027 and 2028. Following this grant, he beneficially owns 58,115 stock options. He was also awarded 5,468 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting, increasing his RSU holdings to 63,583 units. All holdings are reported as directly owned.
Catalyst Pharmaceuticals (CPRX) reported an equity award for its Chief Medical Officer on a Form 4. On November 20, 2025, the officer received options to purchase 98,652 shares of common stock at an exercise price of $22.77 per share, expiring on November 20, 2032. The grant also included 29,776 restricted stock units (RSUs), each representing one share of common stock upon vesting.
The derivative securities vest in three equal parts: one‑third on November 20, 2026, one‑third on November 20, 2027, and one‑third on November 20, 2028. After these awards, the officer beneficially owns 238,360 options and 268,136 RSUs in total, aligning compensation with the company’s long-term stock performance.
Catalyst Pharmaceuticals (CPRX) reported that it issued a press release on November 5, 2025 announcing results for the three and nine months ended September 30, 2025, along with a business update. The press release is furnished as Exhibit 99.1. This routine update signals that quarterly and year-to-date performance details are available via the attached exhibit, which also serves as the company’s formal communication of its latest operating highlights.
Catalyst Pharmaceuticals (CPRX) reported stronger Q3 2025 results. Total revenue reached $148.4 million, up from $128.7 million a year ago, driven by FIRDAPSE ($92.2 million), AGAMREE ($32.4 million), and FYCOMPA ($23.8 million). Operating income was $66.3 million and net income was $52.8 million, with diluted EPS of $0.42 versus $0.35 last year.
For the nine months, revenue rose to $436.4 million from $349.9 million, and net income increased to $161.6 million from $108.0 million. Cash and cash equivalents were $689.9 million, supported by $163.8 million in operating cash flow year-to-date. The balance sheet shows total assets of $1.05 billion, liabilities of $131.4 million, and stockholders’ equity of $920.2 million. Shares outstanding were 122,912,387 as of November 3, 2025.
Brian Elsbernd, Chief Compliance/Legal Officer and Director of Catalyst Pharmaceuticals, reported option exercises and an open-market sale on 09/08/2025. He exercised 112,475 options at an exercise price of $2.24 per share, resulting in the acquisition of 112,475 common shares. To fund the exercise price and tax withholding, 30,000 shares were sold on the open market at a weighted average price of $20.30 (sales ranged from $20.225 to $20.315). Following these transactions, Mr. Elsbernd beneficially owned 271,039 shares directly and reported 846,609 derivative securities (options) beneficially owned. The options reported vested in three annual tranches beginning December 19, 2019.
FAQ
What is the current stock price of Catalyst Pharmaceuticals (CPRX)?
What is the market cap of Catalyst Pharmaceuticals (CPRX)?
